CytomX Therapeutics Inc (CTMX) Hits New 1-Year High After Analyst Upgrade
- Author: Joanne Flowers Mar 21, 2017,
Mar 21, 2017, 17:42
Several sell side analysts reviewed their recommendations on Nektar Therapeutics (NKTR) where 0 analyst have rated the stock as Strong Buy, 0 analysts said it's a Buy, 0 rated the stock as Hold, 0 analysts reported Underperform and 0 analysts gave their recommendations as Sell.
Want to see what other hedge funds are holding CTMX? Company insiders own 6.10% of the company's stock.
The 52-week high of the share price is -7.75% and 52-week low of the share price is 153.68%.
"As a new molecule, NKTR-181 has a highly differentiated profile with the potential to be one of the most important advancements in pain medicine", said Howard W. Robin, Nektar Therapeutics' President and Chief Executive Officer. Perceptive Advisors LLC acquired a new position in shares of CytomX Therapeutics during the fourth quarter worth $10,152,000. The Average Volume (3 months) is 1.23 Million.
The current consensus rating on CytomX Therapeutics (NASDAQ:CTMX) is Hold (Score: 2.20) with a consensus target price of $32.00 per share, a potential 110.80% upside. Instinet now has a sell rating on the stock. Strs Ohio increased its position in Nektar Therapeutics by 39.4% in the third quarter. Following the completion of the transaction, the insider now owns 16,322 shares of the company's stock, valued at $244,830. Overall the consensus ratings were for Buy as compared to Buy rating in last month, courtesy to WSJ.
On 11/28/2016 Ix L.P. Canaan, Director, sold 38,459 with an average share price of $11.56 per share and the total transaction amounting to $444,586.04.
During the open-label titration period, study participants with pain scores of between 5 and 9 on the Numeric Rating Scale (NRS) of 0 to 10 were titrated on NKTR-181 tablets (100 mg to 400 mg twice daily) until they experienced an adequate and sustained pain response (i.e., a drop of at least two points and a pain score below 4 on the NRS).
The surge came on the heels of the company announcing positive results from a late-stage trial evaluating its opioid analgesic, NKTR-181, a next-generation painkiller that relieves pain without the euphoric high associated with traditional opioids. The disclosure for this sale can be found here.
Shares of CytomX Therapeutics closed the previous trading session at 18.97 up +3.79 24.97% with 280,023 shares trading hands.
For the quarter ending 11/03/2016, The Analyst projected that the company could deliver EPS of -0.35 while the company provided its Actual EPS of -0.32 showing a difference of 0.03 Percent between the Estimated and Actual EPS.
Nektar Therapeutics has a 50 day moving average of 13.78 and a 200 day moving average of 14.35. Nektar Therapeutics had a negative net margin of 98.87% and a negative return on equity of 8,769.15%. Price per earning (ttm) stands at 0. The firm's revenue for the quarter was down 4.9% compared to the same quarter past year.
At the movement CytomX Therapeutics, Inc. On a consensus basis, analysts have given a recommendation of 1.50 on company shares. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are created to enable the development of new molecular entities that target known mechanisms of action.